## Lam Research Corporation Reports Financial Results for the Quarter Ended March 26, 2017

 2017 quarter").

Highlights for the March 2017 quarter were as follows:

- Shipments of $\$ 2.41$ billion and revenue of $\$ 2.15$ billion.
- U.S. GAAP gross margin of $45.1 \%$, U.S. GAAP operating margin of $25.0 \%$, and U.S. GAAP diluted EPS of $\$ 3.10$.
- Non-GAAP gross margin of $46.1 \%$, non-GAAP operating margin of $26.9 \%$, and non-GAAP diluted EPS of $\$ 2.80$.


## Key Financial Data for the Quarters Ended

## March 26, 2017 and December 25, 2016

(in thousands, except per-share data, percentages, and basis points)

## U.S. GAAP

|  | March 2017 |  |  | December 2016 |  |  | Change Q/Q |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Shipments | \$ | 2,412,656 |  | \$ | 1,922,549 |  | $+25$ | \% |
| Revenue | \$ | 2,153,995 |  | \$ | 1,882,299 |  | $+14$ | \% |
| Gross margin as percentage of revenue | 45.1 |  | \% | 45.0 |  | \% | $+10$ |  |
| Operating margin as percentage of revenue | 25.0 |  | \% | 23.4 |  | \% | $+160$ |  |
| Diluted EPS | \$ | 3.10 |  | \$ | 1.81 |  | $+71$ | \% |

## Non-GAAP

|  | March 2017 |  |  | December 2016 |  |  | Change Q/Q |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Shipments | \$ | 2,412,656 |  | \$ | 1,922,549 |  | $+25$ | \% |
| Revenue | \$ | 2,153,995 |  | \$ | 1,882,299 |  | $+14$ | \% |
| Gross margin as percentage of revenue | 46.1 |  | \% | 46.4 |  | \% | - 30 bps |  |
| Operating margin as percentage of revenue | 26.9 |  | \% | 26.0 |  | \% | $+90 \mathrm{bps}$ |  |
| Diluted EPS | \$ | 2.80 |  | \$ | 2.24 |  | $+25$ | \% |

## U.S. GAAP Financial Results




 business combination.

## Non-GAAP Financial Results



 2016 quarter.

 said Martin Anstice, Lam Research's President and Chief Executive Officer. "Our outlook for the year has improved, and we are increasingly convinced by the potential for sustainable value creation from long-term diverse and secular technology demand trends."

## Balance Sheet and Cash Flow Results



 notes; approximately $\$ 73$ million of dividends paid to stockholders; and approximately $\$ 44$ million of capital expenditures.
 the March 2017 quarter increased to $\$ 527$ million as compared to $\$ 408$ million at the end of the December 2016 quarter. Lam's deferred revenue balance does not include



## Geographic Distribution

The geographic distribution of shipments and revenue during the March 2017 quarter is shown in the following table:

| Korea | 35 | \% | 34 | \% |
| :---: | :---: | :---: | :---: | :---: |
| Taiwan | 22 | \% | 28 | \% |
| China | 15 | \% | 11 | \% |
| Japan | 15 | \% | 11 | \% |
| United States | 7 | \% | 9 | \% |
| Europe | 3 | \% | 4 | \% |
| Southeast Asia | 3 | \% | 3 | \% |

## Outlook

For the June 2017 quarter, Lam is providing the following guidance:

|  | U.S. GAAP |  |  |  |  | Reconciling Items |  |  | Non-GAAP |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Shipments | \$2.5 Billion |  | +/- | \$100 Million |  | - |  |  | \$2.5 Billion |  | +/- | \$100 Million |  |
| Revenue | \$2.3 Billion |  | +/- | \$100 Million |  | - |  |  | \$2.3 Billion |  | +/- | \$100 Million |  |
| Gross margin | 45.1 | \% | +/- | 1 | \% | \$ | 21 | Million | 46.0 | \% | +/- | 1 | \% |
| Operating margin | 25.3 | \% | +/- | 1 | \% | \$ | 39 | Million | 27.0 | \% | +/- | 1 | \% |
| Net income per diluted share | \$2.73 |  | +/- | \$0.12 |  | \$ | 38 | Million | \$3.00 |  | +/- | \$0.12 |  |
| Diluted share count | 184 Million |  |  |  |  | 4 |  | Million | 180 Million |  |  |  |  |



 date of this release. Actual results will vary from this model and the variations may be material. Reconciling items included above are as follows:

- Gross margin - amortization related to intangible assets acquired in the Novellus transaction, $\$ 21$ million.
- Operating margin - amortization related to intangible assets acquired in the Novellus transaction, $\$ 37$ million; costs associated with business process reengineering, $\$ 2$ million; totaling $\$ 39$ million.
 costs associated with business process reengineering, $\$ 2$ million; and associated tax benefit for non-GAAP items (\$7) million; totaling $\$ 38$ million.
- Diluted share count - impact of a note hedge issued contemporaneously with the convertible notes due 2018,4 million shares.


## Use of Non-GAAP Financial Results




 Tencor acquisition funding net interest expense, and costs related to the early termination of the KLA-Tencor acquisition funding.


 results are included at the end of this press release and on the Company's website at http://investor.lamresearch.com.

## Caution Regarding Forward-Looking Statements









 material way. The Company undertakes no obligation to update the information or statements made in this release.

## About Lam Research




 whose common stock trades on the Nasdaq Global Select Market ${ }^{S M}$ under the symbol LRCX. For more information, please visit http://www.lamresearch.com. (LRCX-F).

Consolidated Financial Tables Follow.

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data and percentages)
(unaudited)


Number of
shares used
in per share
calculations:

| Basic | 163,408 |  | 162,659 |  | 159,039 |  | 162,225 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Diluted | 185,094 |  | 183,543 |  | 174,373 |  | 182,885 |  |
| Cash dividend declared per common share | \$ | 0.45 | \$ | 0.45 | \$ | 0.30 | \$ | 1.20 |

## LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

|  | $\begin{aligned} & \text { March 26, } \\ & 2017 \end{aligned}$ |  | $\begin{aligned} & \text { December 25, } \\ & 2016 \end{aligned}$ |  | $\begin{aligned} & \text { June 26, } \\ & 2016 \end{aligned}$ |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | (unaudited) |  | (unaudited) |  | (1) |  |  |  |
| ASSETS |  |  |  |  |  |  |  |  |
| Cash and cash equivalents | \$ | 2,128,570 | \$ | 2,503,960 | \$ | 5,039,322 |  |  |
| Investments | 3,755,036 |  | 3,329,425 |  | 1,788,612 |  |  |  |
| Accounts receivable, net | 1,636,090 |  | 1,426,307 |  | 1,262,145 |  |  |  |
| Inventories | 1,133,196 |  | 1,018,891 |  | 971,911 |  |  |  |
| Other current assets | 223,056 |  | 225,291 |  | 151,160 |  | 12 | ) |
| Total current assets | 8,875,948 |  | 8,503,874 |  | 9,213,150 |  |  |  |
| Property and equipment, net | 675,707 |  | 672,553 |  | 639,608 |  |  |  |
| Restricted cash and investments | 256,157 |  | 255,175 |  | 250,421 |  |  |  |
| Goodwill and intangible assets | 1,835,150 |  | 1,873,581 |  | 1,951,197 |  |  |  |
| Other assets | 232,224 |  | 215,876 |  | 209,939 |  | 12 | ) |
| Total assets | \$ | 11,875,186 | \$ | 11,521,059 | \$ | 12,264,315 |  |  |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |  |  |  |
| Current portion of convertible notes and capital leases | \$ | 905,288 | \$ | 957,895 | \$ | 947,733 | (2 | ) |
| Other current liabilities | 1,851,451 |  | 1,700,123 |  | 1,470,308 |  |  |  |
| Total current liabilities | 2,756,739 |  | 2,658,018 |  | 2,418,041 |  |  |  |
| Long-term debt and capital leases | 1,777,297 |  | 1,768,713 |  | 3,378,129 |  | 12 | ) |
| Income taxes payable | 137,173 |  | 238,968 |  | 231,514 |  |  |  |
| Other long-term liabilities | 282,615 |  | 262,351 |  | 134,562 |  |  |  |
| Total liabilities | 4,953,824 |  | 4,928,050 |  | 6,162,246 |  |  |  |
| Temporary equity, convertible notes | 175,108 |  | 197,313 |  | 207,552 |  |  |  |
| Stockholders' equity (3) | 6,746,254 |  | 6,395,696 |  | 5,894,517 |  |  |  |
| Total liabilities and stockholders' equity | \$ | 11,875,186 | \$ | 11,521,059 | \$ | 12,264,315 |  |  |

(1 ) Derived from audited financial statements.

1. Adjusted for effects of retrospective implementation of ASU 2015-3, regarding the simplification of the presentation of bond issuance costs, which (2 ) requires that bond issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts.
(3 ) Common shares issued and outstanding were 163,969 as of March 26, 2017, 162,357 as of December 25, 2016, and 160,201 as of June 26, 2016 .

## LAM RESEARCH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)

|  | Three Months Ended |  |  |  |  |  | Nine Months Ended |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \text { March 26, } \\ & 2017 \end{aligned}$ |  | $\begin{aligned} & \text { December 25, } \\ & 2016 \end{aligned}$ |  | $\begin{aligned} & \text { March 27, } \\ & 2016 \end{aligned}$ |  | $\begin{aligned} & \text { March 26, } \\ & 2017 \end{aligned}$ |  | $\begin{aligned} & \text { Ma } \\ & \mathbf{2 0} \end{aligned}$ |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |  |  |  |  |  |
| Net income | \$ | 574,713 | \$ | 332,791 | \$ | 143,451 | \$ | 1,171,339 | \$ |


| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Depreciation and amortization | 76,242 |  | 77,065 |  | 73,664 |  | 227,869 |  | 216 |
| Deferred income taxes | 27,619 |  | 34,615 |  | (4,908 | ) | 69,867 |  | (2, ${ }^{\text {a }}$ |
| Equity-based compensation expense | 35,323 |  | 32,255 |  | 34,716 |  | 106,173 |  | $10 \equiv$ |
| Loss on extinguishment of debt | - |  | 36,325 |  | - |  | 36,325 |  | - |
| Amortization of note discounts and issuance costs | 6,136 |  | 6,202 |  | 22,458 |  | 19,168 |  | 55, |
| Other, net | (4,738 | ) | (1,292 | ) | 9,306 |  | 10,777 |  | 29, |
| Changes in operating assets and liabilities | (292,607 | ) | (113,863 | ) | (95,776 | ) | (341,508 | ) | (13 |
| Net cash provided by operating activities | 422,688 |  | 404,098 |  | 182,911 |  | 1,300,010 |  | $92 \epsilon$ |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |  |  |  |  |  |  |  |
| Capital expenditures and intangible assets | (44,116 | ) | (36,513 | ) | (46,007 | ) | (122,608 | ) | (12 |
| Net (purchase) sale of available-forsale securities | (418,566 | ) | (1,990,928 | ) | 181,938 |  | (1,977,744 | ) | 192 |
| (Issuance) repayment of notes receivable | - |  | (500 | ) | (200 | ) | (500 | ) | 7,8 |
| Transfers of restricted cash and investments | $(982$ | ) | 465 |  | - |  | (5,736 | ) | - |
| Other, net | (3,586 | ) | 259 |  | - |  | (11,127 | ) | (6, ${ }^{2}$ |
| Net cash (used for) provided by investing activities | (467,250 | ) | (2,027,217 | ) | 135,731 |  | (2,117,715 | ) | 70, |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |  |  |  |  |  |  |  |
| Principal payments on long-term debt and capital lease obligations and payments for debt issuance costs | (69,227 | ) | (1,616,270 | ) | (8,479 | ) | (1,685,868 | ) | (36 |
| Treasury stock purchases | (216,373 | ) | (67,668 | ) | (20,092 | ) | (285,894 | ) | (13 |
| Dividends paid | (73,337 | ) | (48,397 | ) | (47,539 | ) | (169,786 | ) | (14 |
| Reissuance of treasury stock related to employee | 17,223 |  | - |  | 16,387 |  | 36,543 |  | 35, |


| stock purchase plan |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Proceeds from issuance of common stock | 7,964 |  | 3,121 |  | 308 |  | 12,544 |  | 1,8 |
| Other, net | (70 | ) | (44 | ) | 2,255 |  | (124 | ) | 7,6 |
| Net cash used for financing activities | (333,820 | ) | (1,729,258 | ) | (57,160 | ) | (2,092,585 | ) | (26 |
| Effect of exchange rate changes on cash and cash equivalents | 2,992 |  | (5,364 | ) | 2,666 |  | (462 | ) | (79 |
| Net (decrease) increase in cash and cash equivalents | (375,390 | ) | (3,357,741 | ) | 264,148 |  | (2,910,752 | ) | 730 |
| Cash and cash equivalents at beginning of period | 2,503,960 |  | 5,861,701 |  | 1,967,873 |  | 5,039,322 |  | 1,5 |
| Cash and cash equivalents at end of period | \$ 2,128,570 |  | \$ 2,503,960 |  | \$ 2,232,021 |  | \$ 2,128,570 |  | \$ |

## Non-GAAP Financial Summary

(in thousands, except percentages and per share data)
(unaudited)

|  | Three Months Ended |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \text { March 26, } \\ & 2017 \end{aligned}$ |  |  | $\begin{aligned} & \text { December 25, } \\ & 2016 \end{aligned}$ |  |  |
| Revenue | \$ | 2,153,995 |  | \$ | 1,882,299 |  |
| Gross margin | \$ | 992,654 |  | \$ | 874,174 |  |
| Gross margin as percentage of revenue | 46.1 |  | \% | 46.4 |  | \% |
| Operating expenses | \$ | 414,229 |  | \$ | 384,241 |  |
| Operating income | \$ | 578,425 |  | \$ | 489,933 |  |
| Operating margin as a percentage of revenue | 26.9 |  | \% | 26.0 |  | \% |
| Net income | \$ | 507,751 |  | \$ | 405,190 |  |
| Net income per diluted share | \$ | 2.80 |  | \$ | 2.24 |  |
| Shares used in per share calculation - diluted | 181,539 |  |  | 180,613 |  |  |

## Reconciliation of U.S. GAAP Net Income to Non-GAAP Net Income and U.S. GAAP number of dilutive shares to Non-GAAP number of dilutive shares

## (in thousands, except per share data)

(unaudited)

## Three Months Ended

## March 26

December 25
\$ 574,713
332,791

Pre-tax non-GAAP items:

| Amortization related to intangible assets acquired in Novellus transaction - cost of goods sold | 21,250 |  |  | 21,250 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Product rationalization - cost of goods sold | - |  |  | 6,127 |  |  |
| Costs associated with campus consolidation - research and development | - |  |  | 995 |  |  |
| Product rationalization - research and development | - |  |  | 1,650 |  |  |
| Amortization related to intangible assets acquired in Novellus transaction - selling, general and administrative | 16,083 |  |  | 16,083 |  |  |
| Costs associated with business process reengineering - selling, general and administrative | 2,674 |  |  | - |  |  |
| Litigation settlement - selling general and administrative | - |  |  | 4,000 |  |  |
| KLA-Tencor acquisition funding interest expense, net - other expense, net | - |  |  | 2,682 |  |  |
| Amortization of note discounts - other expense, net | 5,654 |  |  | 5,671 |  |  |
| Costs related to early termination of KLA-Tencor acquisition funding - other expense, net | - |  |  | 34,518 |  |  |
| Net income tax benefit on non-GAAP items | (6,418 |  | ) | (20,577 |  | ) |
| Income tax benefit on conclusion of certain tax matters | (106,205 |  | ) | - |  |  |
| Non-GAAP net income | \$ | 507,751 |  | \$ | 405,190 |  |
| Non-GAAP net income per diluted share | \$ | 2.80 |  | \$ | 2.24 |  |
| U.S. GAAP number of shares used for per diluted share calculation | 185,094 |  |  | 183,543 |  |  |
| Effect of convertible note hedge | (3,555 |  | ) | (2,930 |  | ) |
| Non-GAAP number of shares used for per diluted share calculation | 181,539 |  |  | 180,613 |  |  |

Reconciliation of U.S. GAAP Gross Margin, Operating Expenses and Operating Income to Non-GAAP Gross Margin, Operating Expenses and Operating Income
(in thousands, except percentages)
(unaudited)

|  | Three Months Ended |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \text { March 26, } \\ & 2017 \end{aligned}$ |  |  | $\begin{aligned} & \text { December 25, } \\ & 2016 \end{aligned}$ |  |  |
| U.S. GAAP gross margin | \$ | 971,404 |  | \$ | 846,797 |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction | 21,250 |  |  | 21,250 |  |  |
| Product rationalization | - |  |  | 6,127 |  |  |
| Non-GAAP gross margin | \$ | 992,654 |  | \$ | 874,174 |  |
| U.S. GAAP gross margin as a percentage of revenue | 45.1 |  | \% | 45.0 |  | \% |
| Non-GAAP gross margin as a percentage of revenue | 46.1 |  | \% | 46.4 |  | \% |
| U.S. GAAP operating expenses | \$ 432,986 |  |  | \$ 406,969 |  |  |
| Pre-tax non-GAAP items: |  |  |  |  |  |  |
| Amortization related to intangible assets acquired in Novellus transaction | (16,083 |  | ) | (16,083 |  | ) |
| Costs associated with business process reengineering | (2,674 |  | ) | - |  |  |
| Costs associated with campus consolidation | - |  |  | $(995$ |  | ) |
| Product rationalization | - |  |  | (1,650 |  | ) |
| Litigation settlement | - |  |  | (4,000 |  | ) |
| Non-GAAP operating expenses | \$ | 414,229 |  | \$ | 384,241 |  |
| Non-GAAP operating income | \$ | 578,425 |  | \$ | 489,933 |  |
| U.S. GAAP operating margin as percent of revenue | 25.0 |  | \% | 23.4 |  | \% |

Lam Research Corporation Contacts:

Satya Kumar, Investor Relations, phone: 510-572-1615, e-mail: investor.relations@lamresearch.com

Source: Lam Research

News Provided by Acquire Media
https://newsroom.lamresearch.com/2017-04-18-Lam-Research-Corporation-Reports-Financial-Results-for-the-Quarter-Ended-March-26.-2017

